BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 15199892)

  • 1. Urinary symptoms and prostate cancer treatment.
    Health News; 2004 Jun; 10(6):2. PubMed ID: 15199892
    [No Abstract]   [Full Text] [Related]  

  • 2. Preimplant predictive factors of urinary retention after iodine 125 prostate brachytherapy.
    Mabjeesh NJ; Chen J; Stenger A; Matzkin H
    Urology; 2007 Sep; 70(3):548-53. PubMed ID: 17905113
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Re: Late urinary morbidity with high dose prostate brachytherapy as a boost to conventional external beam radiation therapy for local and locally advanced prostate cancer.
    Deger S
    J Urol; 2004 Sep; 172(3):1198; author reply 1198. PubMed ID: 15311075
    [No Abstract]   [Full Text] [Related]  

  • 4. Predictive factors of acute urinary retention requiring catheterization following 125I prostate brachytherapy.
    Ohashi T; Yorozu A; Toya K; Saito S; Momma T
    Jpn J Clin Oncol; 2006 May; 36(5):285-9. PubMed ID: 16698803
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Editorial comment.
    Pinkawa M
    J Urol; 2010 Feb; 183(2):639; discussion 639-40. PubMed ID: 20018310
    [No Abstract]   [Full Text] [Related]  

  • 6. Editorial comment.
    Williams SG
    J Urol; 2010 Feb; 183(2):639; discussion 639-40. PubMed ID: 20018309
    [No Abstract]   [Full Text] [Related]  

  • 7. Severity categories of the International Prostate Symptom Score before, and urinary morbidity after, permanent prostate brachytherapy.
    Gutman S; Merrick GS; Butler WM; Wallner KE; Allen Z; Galbreath RW; Adamovich E
    BJU Int; 2006 Jan; 97(1):62-8. PubMed ID: 16336330
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Urinary and rectal complications of contemporary permanent transperineal brachytherapy for prostate carcinoma with or without external beam radiation therapy.
    Sarosdy MF
    Cancer; 2004 Aug; 101(4):754-60. PubMed ID: 15305406
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Usefulness of urethral endoprosthesis in the management of urinary retention after brachytherapy for localized prostate cancer].
    Kerkeni W; Chahwan C; Lenormand C; Dubray B; Benyoucef A; Pfister C
    Prog Urol; 2014 Mar; 24(3):164-6. PubMed ID: 24560204
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Factors predicting for urinary morbidity following 125iodine transperineal prostate brachytherapy.
    Williams SG; Millar JL; Duchesne GM; Dally MJ; Royce PL; Snow RM
    Radiother Oncol; 2004 Oct; 73(1):33-8. PubMed ID: 15465143
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Peak flow rate is the best predictor of acute urinary retention following prostate brachytherapy: our experience and literature review.
    Ikeda T; Shinohara K
    Int J Urol; 2009 Jun; 16(6):558-60. PubMed ID: 19456987
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Non-obstructive urinary retention--an unusual presentation of prostate cancer.
    Bandi S; Krishna Sayana M; Ahmed el-N
    Scand J Urol Nephrol; 2005; 39(6):518-9. PubMed ID: 16303730
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The pathophysiology of lower urinary tract symptoms after brachytherapy for prostate cancer.
    Blaivas JG; Weiss JP; Jones M
    BJU Int; 2006 Dec; 98(6):1233-7; discussion 1237. PubMed ID: 17125481
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prophylactic tamsulosin (Flomax) in patients undergoing prostate 125I brachytherapy for prostate carcinoma: final report of a double-blind placebo-controlled randomized study.
    Elshaikh MA; Ulchaker JC; Reddy CA; Angermeier KW; Klein EA; Chehade N; Altman A; Ciezki JP
    Int J Radiat Oncol Biol Phys; 2005 May; 62(1):164-9. PubMed ID: 15850917
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Summary of simultaneous irradiation for prostate cancer.
    Critz FA
    Urology; 2004 Oct; 64(4):633-6. PubMed ID: 15491686
    [No Abstract]   [Full Text] [Related]  

  • 16. Factors associated with the frequency of self-intermittent catheterization after prostate brachytherapy.
    Schwartz DJ; Schild SE; Wong WW; Vora SA
    Int J Radiat Oncol Biol Phys; 2005 Jan; 61(1):60-3. PubMed ID: 15629594
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Side effects of permanent I125 prostate seed implants in 667 patients treated in Leeds.
    Bottomley D; Ash D; Al-Qaisieh B; Carey B; Joseph J; St Clair S; Gould K
    Radiother Oncol; 2007 Jan; 82(1):46-9. PubMed ID: 17161481
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Brachytherapy: the surgeon's perspective.
    Henderson A; Sooriakumaran P; Laing RW; Langley SE
    BJU Int; 2004 May; 93(7):1118. PubMed ID: 15142184
    [No Abstract]   [Full Text] [Related]  

  • 19. Dynamic dose-feedback prostate brachytherapy in patients with large prostates and/or planned transurethral surgery before implantation.
    Acher PL; Popert R; Morris SL; Potters L; Austin-Smith SL; Johnson UH; Nichol JE; Beaney RP
    BJU Int; 2007 May; 99(5):1066-71. PubMed ID: 17233801
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Brachytherapy for prostate cancer: is the pretreatment prostate volume important?
    Meyer JP; Bell CR; Elwell C; Kunkler RB
    BJU Int; 2008 Dec; 102(11):1585-8. PubMed ID: 18990138
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.